The University of Alabama at Birmingham (UAB) is now enrolling participants in the ADAPT clinical trial, which is designed to test adaptive treatment strategies for individuals who have recently relapsed after attempting to quit smoking. The study aims to provide accessible and effective support for smoking cessation through a fully remote format.
Study Design and Interventions
The ADAPT trial offers participants the chance to try varenicline, a prescription medication known for its efficacy in smoking cessation. Alternatively, participants may use nicotine replacement therapies, such as patches and lozenges, to manage withdrawal symptoms and cravings. The trial involves an initial online screening process, followed by eight contacts over a six-month period. This remote design ensures that participants can engage in the study from the comfort of their own homes, removing geographical barriers to participation.
Eligibility and Compensation
Individuals who smoke cigarettes daily may be eligible to participate in the ADAPT study. Eligible participants will receive compensation for their time and involvement in the research. The study is actively recruiting participants through an online portal, where interested individuals can complete a screening questionnaire to determine their eligibility.
Significance of the Research
Smoking remains a significant public health challenge, with high rates of relapse among those attempting to quit. The ADAPT trial seeks to address this issue by exploring adaptive treatment approaches that can be tailored to individual needs, potentially improving long-term smoking cessation rates. By offering varenicline and nicotine replacement therapies within a structured, remote support system, the study aims to provide comprehensive assistance to individuals struggling with smoking relapse.
